FILE:CELG/CELG-8K-20070109201031.txt.gz
EVENTS:	Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers	Financial Statements and Exhibits
TEXT:
ITEM: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
ITEM: Financial Statements and Exhibits
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 7, 2007 CELGENE CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-16132 22-2711928 - -------------------------------------------------------------------------------- (State or other jurisdiction of (Commission File Number) (IRS Employer incorporation) Identification No.) 86 Morris Avenue, Summit, New Jersey 07901 - -------------------------------------------------------------------------------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (908) 673-9000 --------------------------------------------------------------- (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): |_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. On January 8, 2007, Celgene Corporation announced the election of James J. Loughlin to the Company's Board of Directors effective January 7, 2007. Mr. Loughlin is an experienced corporate director with a distinguished 40-year career with KPMG LLP, one of the world's leading professional accounting and business consulting firms. Mr. Loughlin started his career at KPMG LLP in 1964 and reached National Director of the Pharmaceuticals Practice, one of the highest levels of corporate management and governance within the Practice. Mr. Loughlin served a five-year term as member of the Board of Directors of KPMG LLP. Mr. Loughlin will serve as a member of the Audit Committee of the Celgene Board of Directors. As a Board member, Mr. Loughlin will receive an annual fee of $30,000 and $2,500 for each Board Meeting attended in person or $500 for each Board Meeting attended telephonically. In addition, Mr. Loughlin will receive $4,000 annually as a member of the Audit Committee. Under the 1995 Non-Employee Directors' Incentive Plan, Mr. Loughlin will be granted a non-qualified option to purchase 20,000 shares of the Company's common stock, which vest in four equal annual installments commencing on the first anniversary of the date of grant. Under the 1995 Non-Employee Directors' Incentive Plan, Mr. Loughlin will also be eligible to receive quarterly grants of 3,750 options aggregating 15,000 options annually, which vest one year from the date of grant. Attached hereto and incorporated herein by reference as Exhibit 99.1 is the Press Release announcing such action. ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS. Exhibit 99.1 Press Release dated January 8, 2007 announcing the election of James J. Loughlin to the Company's Board of Directors. SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CELGENE CORPORATION Date: January 10, 2007 By: /s/ David W. Gryska -------------------------------------- Name: David W. Gryska Title: Chief Financial Officer
EXHIBIT INDEX Exhibit No. Description - ----------- ----------- 99.1 Press Release dated January 8, 2007 announcing the election of James J. Loughlin to the Company's Board of Directors.

Exhibit 99.1 Contact: Robert J. Hugin Brian P. Gill President and Vice President, Chief Operating Officer Corporate Communications Celgene Corporation Celgene Corporation (908) 673-9102 (908) 673-9530 CELGENE CORPORATION ELECTS JAMES J. LOUGHLIN TO BOARD OF DIRECTORS SUMMIT, NJ - (JANUARY 8, 2007) - CELGENE CORPORATION (NASDAQ: CELG) announced the election of James J. Loughlin to the Company's Board of Directors. Mr. Loughlin is an experienced corporate director with a distinguished 40-year career with one of the world's leading professional accounting and business consulting firms where he reached the highest levels of corporate management and governance from entry level in 1964 to National Director of the Pharmaceuticals Practice, including a five-year term as member of the Board of Directors of KPMG LLP. Mr. Loughlin served as chairman of the Pension and Investment Committee of the KPMG Board from 1995 through 2001. As Partner, Mr. Loughlin led multinational audits of pharmaceutical and financial services companies. Mr. Loughlin also served as Partner in charge of Human Resources, Chairman of the Personnel and Professional Development Committee, Secretary and Trustee of the Peat Marwick Foundation and a member of the Pension, Operating and Strategic Planning Committees. "Celgene will benefit substantially from Jim's extensive financial and business consulting expertise," said Sol. J. Barer, Ph.D., Chairman and Chief Executive Officer of Celgene Corporation. "He is a welcomed addition to the Board and we look forward to his valuable contributions." ABOUT CELGENE Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company's website at www.celgene.com. THIS RELEASE CONTAINS CERTAIN FORWARD-LOOKING STATEMENTS WHICH INVOLVE KNOWN AND UNKNOWN RISKS, DELAYS, UNCERTAINTIES AND OTHER FACTORS NOT UNDER THE COMPANY'S CONTROL, WHICH MAY CAUSE ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS OF THE COMPANY TO BE MATERIALLY DIFFERENT FROM THE RESULTS, PERFORMANCE OR OTHER EXPECTATIONS IMPLIED BY THESE FORWARD-LOOKING STATEMENTS. THESE FACTORS INCLUDE RESULTS OF CURRENT OR PENDING RESEARCH AND DEVELOPMENT ACTIVITIES, ACTIONS BY THE FDA AND OTHER REGULATORY AUTHORITIES, AND THOSE FACTORS DETAILED IN THE COMPANY'S FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION SUCH AS 10K, 10Q AND 8K REPORTS. # # #


